Nanoviricides (NNVC) EPS (Basic) Growth (3y) (2013 - 2026)
Nanoviricides (NNVC) EPS (Basic) Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 64.84% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 18.44% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.21% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.73% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -26.87% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 67.51% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -38.31% |
| 10 | Nanoviricides | 28.74 Mn | 25.53 Mn | - | 13.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 54.52% |
| Dec 31, 2025 | 51.82% |
| Sep 30, 2025 | 51.22% |
| Jun 30, 2025 | 3.20% |
| Mar 31, 2025 | 3.33% |
| Dec 31, 2024 | 5.36% |
| Sep 30, 2024 | -0.59% |
| Jun 30, 2024 | -1.94% |
| Mar 31, 2024 | 5.58% |
| Dec 31, 2023 | 5.03% |
| Sep 30, 2023 | 8.65% |
| Jun 30, 2023 | 1.78% |
| Mar 31, 2023 | 6.95% |
| Dec 31, 2022 | -26.24% |
| Sep 30, 2022 | -30.69% |
| Jun 30, 2022 | 36.97% |
| Mar 31, 2022 | 36.08% |
| Dec 31, 2021 | 36.24% |
| Sep 30, 2021 | 24.74% |
| Jun 30, 2021 | 27.96% |